妇科癌症跨组 (GCIG) 子宫内膜癌临床研究共识会议 (ECCC) 于 2023 年 11 月 2-3 日在韩国仁川举行。会议旨在为子宫内膜癌的未来试验制定共识声明，以实现设计上的统一元素，选择重要问题，并确定未满足的需求。所有 33 个 GCIG 成员小组都参与了四个主题组内 18 项声明的制定、完善和最终确定，涉及高危疾病的辅助治疗；治疗转移性和复发性疾病；针对罕见子宫内膜癌亚组和特殊情况的试验设计；以及资源匮乏环境下试验的具体方法和适应性。此外，还确定了八个未满足需求的领域。这是第一次 GCIG 共识会议，患者倡导者和包容性、多样性、公平性和可及性方面的专家参与了流程和产出的各个方面。还选择了四名早期职业调查员参与，确保他们代表不同的 GCIG 成员群体和地区。 18 项声明中的 16 项获得了一致同意，其余两项的一致性达到 97%。使用之前卵巢癌共识会议所描述的方法，本次会议甚至不需要一份少数派声明。所有代表积极参与声明的准备、讨论和完善，所获得的高接受率证实了全球学术环境中的共识进展，并期望 ECCC 将导致更大程度的协调、实现、包容和解决全球子宫内膜癌及其他子宫内膜癌患者的临床研究需求未得到满足。版权所有 © 2024 Elsevier Ltd。保留所有权利，包括文本和数据挖掘、人工智能培训和类似技术的权利。

The Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Consensus Conference on Clinical Research (ECCC) was held in Incheon, South Korea, Nov 2-3, 2023. The aims were to develop consensus statements for future trials in endometrial cancer to achieve harmonisation on design elements, select important questions, and identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and finalisation of 18 statements within four topic groups, addressing adjuvant treatment in high-risk disease; treatment for metastatic and recurrent disease; trial designs for rare endometrial cancer subgroups and special circumstances; and specific methodology and adaptation for trials in low-resource settings. In addition, eight areas of unmet need were identified. This was the first GCIG Consensus Conference to include patient advocates and an expert on inclusion, diversity, equity, and access to take part in all aspects of the process and output. Four early-career investigators were also selected for participation, ensuring that they represented different GCIG member groups and regions. Unanimous consensus was obtained for 16 of the 18 statements, with 97% concordance for the remaining two. Using the described methodology from previous Ovarian Cancer Consensus Conferences, this conference did not require even one minority statement. The high acceptance rate following active involvement in the preparation, discussion, and refinement of the statements by all representatives confirmed the consensus progress within a global academic setting, and the expectation that the ECCC will lead to greater harmonisation, actualisation, inclusion, and resolution of unmet needs in clinical research for individuals living with and beyond endometrial cancer worldwide.Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.